AST SpaceMobile stock dives 10% as Scotiabank downgrade hits ASTS valuation

AST SpaceMobile stock dives 10% as Scotiabank downgrade hits ASTS valuation

New York, January 7, 2026, 13:29 EST — Regular session

AST SpaceMobile (ASTS) shares fell 10.2% to $87.55 in regular trading on Wednesday after Scotiabank cut its rating. The stock has traded between $95.25 and $86.20 so far, with about 15 million shares changing hands. Finviz

Scotiabank analyst Andres Coello downgraded the stock to “Sell” and set a $45.60 price target, Barron’s reported. Coello flagged valuation, with the stock trading at more than 100 times projected 2026 sales and about 20 times estimated 2029 EBITDA, even as the company is not expected to post positive operating profits until 2027, the report said. Barron’s

The timing matters because AST’s rally has turned it into a litmus test for how much investors will pay for early-stage space and telecom bets that are heavy on capex and light on near-term earnings. When one broker starts calling time on the valuation, the stock’s momentum can crack fast.

AST is building a low-Earth-orbit satellite constellation designed to deliver cellular broadband directly to everyday smartphones — often called “direct-to-device,” because it aims to connect without a special satellite phone or dish. AST SpaceMobile

But Coello argued the path to scale is long and expensive, pointing to the lack of retail customers and the need to deploy roughly 50 satellites to offer continuous service in some markets by late 2026 or early 2027, Investing.com reported. He said the shares had pushed to “irrational levels,” and warned investors could be waiting until 2028 or 2029 for meaningful free cash flow. Investing

Stock Market Today

  • Parabilis Medicines raises $305 million as CEO warms to an IPO
    January 8, 2026, 7:28 AM EST. Parabilis Medicines has raised $305 million in a new funding round, helping move its lead cancer drug candidate into late-stage testing. The round is a Series F, signaling the company has sought external capital at least six times while remaining private. CEO Mathai Mammen has signaled renewed interest in an IPO after previously saying there was no need to go public. The company, formerly FogPharma, is pursuing a corkscrew-shaped peptide approach intended to breach cells more effectively, including tumors. The capital supports advancing the program and sustaining the private development path that has defined the company since inception.
Why First Solar stock is sliding today: Jefferies downgrade puts 2026 bookings in the spotlight
Previous Story

Why First Solar stock is sliding today: Jefferies downgrade puts 2026 bookings in the spotlight

Qorvo (QRVO) stock drops 8% as Apple-linked chip names slide ahead of U.S. jobs report
Next Story

Qorvo (QRVO) stock drops 8% as Apple-linked chip names slide ahead of U.S. jobs report

Go toTop